Efffects of nedaplatin concurrent chemotherapy on the expression levels of uPA, VEGF and Ki-67 in patients with cervical cancer at middle stage or advanced stage
SHU Pingfeng
Abstract：Objective To observe the efffects of nedaplatin concurrent chemotherapy on the expression levels of uPA , VEGF and Ki-67 in patients with cervical cancer at middle stage or advanced stage .Methods Eighty patients with primary cervical cancer who were admitted and treated in our hospital from March 2011 to March 2012 were randomly divided into observation group ( n =40 ) and control group ( n =40 ) .The patients in observation group were treated by nedaplatin concurrent chemotherapy ,however ,the patients in control group were treated by radiotherapy only .The therapeutic effects and positive expression rates of uPA ,VEGF and Ki-67 before and after treatment were observed and compared between two groups . Results The total effective rate in observation group was 95.0%,which was significantly higher than that (80.0%) in control group ( P <0.05).During follow -up there were significant differences in survival rate ,relapse rate and distant metastasis rate between two groups ( P <0.05).The positive expression rates of uPA ,VEGF and Ki-67 in cancerous tissues of patients with cervical cancer were significantly higher than those in normal cervical tissues ( P <0.05).The positive expression rates of uPA,VEGF and Ki-67 were obviously decreased after treatment in both groups ( P <0.05),moreover,the decrease degree in onservation group was more obvious than that in control group ( P <0.05).The effective rates in observation group with positive Ki-67 were significantly higher than those in observation group with negative Ki-67 ( P <0.05).However there were no significant differences in the incidence rates of adverse reactions between two groups ( P >0.05).Conclusion The nedaplatin concurrent chemotherapy can obviously decrease the positive expression rates of uPA , VEGF and Ki-67 in patients with cervical cancer at middle stage or advanced stage and can enhance therapeutic effect ,without obvious adverse reactions ,thus,which is worth using widely in clinical practice .
Keywords：concurrent chemoradiotherapycervix neoplasmsvascular endothelial growth factorurokinase-type plasminogen activatorKi-67
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 495-499 )